Research conducted by the Tufts Center for the Study of Drug Development (CSDD) found that protocol complexity correlates with longer clinical study times and poorer patient recruitment. Therefore, drug development companies are working to increase clinical trial efficiency by streamlining protocols, according to Tufts CSDD. The April Tufts CSDD R&D Management Report outlines key points for how drug developers can optimize protocol design. To read a summary of the report from pharmpro.com, click here.
Single IRB – A Guide to the Common Rule sIRB Mandate
The sIRB requirement is active. Is your study affected?
Clinical Research Accelerated
You need high quality, timely board reviews so that you can get your study in the clinic.
Recent Posts
Pearl IRB 2023 Year-End Schedule
Snowball Sampling: Is it ethical to pay your study subjects to recruit participants on your behalf?
Improving Exempt Submissions: 7 Tips to Reduce Revision Requests
Common Rule Exceptions to the Use of a Single IRB for Multi-site Research Ends After May 11, 2023
Pearl IRB 2022 Year-End Schedule